Blood markers and gene testing to predict repeat stroke after brain artery stenting
Studies blood markers and gene tests in adults with a brain artery stent.
Plain-language title generated from the registry record
Registry title: Biomarkers of Clopidogrel Resistance for Predicting Ischemic Recurrence After Cerebral Artery Stenting
Key facts
- Where
- Nanjing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07028775, who can take part
Where in China
- Nanjing First HospitalNanjing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nanjing First Hospital, Nanjing Medical University
- Trial code
- NCT07028775
- Record updated
- 19 June 2025
- Original description
This study aims to evaluate the clinical significance of clopidogrel resistance-associated biomarkers (TMAO, C1q, and C4BPα) in patients receiving cerebral artery stents, and to develop an integrated predictive model incorporating these novel biomarkers along with CYP2C19 genotyping data for accurate clopidogrel resistance prediction in Chinese populations. By establishing this multidimensional assessment system, we intend to provide reliable risk stratification for post-stenting ischemic events and in-stent restenosis, ultimately facilitating personalized antiplatelet therapy decisions in cerebrovascular interventions. The proposed model may serve as a valuable clinical tool to optimize treatment strategies and improve outcomes for stented patients at risk of clopidogrel resistance.Read full original descriptionShow less
Clinical Application Study and Evaluation of Clopidogrel Resistance-Related Biomarkers in Predicting the Recurrence of Ischemic Events After Cerebral Artery Stenting
This study aims to evaluate the clinical significance of clopidogrel resistance-associated biomarkers (TMAO, C1q, and C4BPα) in patients receiving cerebral artery stents, and to develop an integrated predictive model incorporating these novel biomarkers along with CYP2C19 genotyping data for accurate clopidogrel resistance prediction in Chinese populations. By establishing this multidimensional assessment system, we intend to provide reliable risk stratification for post-stenting ischemic events and in-stent restenosis, ultimately facilitating personalized antiplatelet therapy decisions in cerebrovascular interventions. The proposed model may serve as a valuable clinical tool to optimize treatment strategies and improve outcomes for stented patients at risk of clopidogrel resistance.
Inclusion: Age 18-80 years, with ischemic stroke due to atherosclerotic cerebrovascular stenosis; Scheduled for cerebral artery stenting with standard dual antiplatelet therapy (aspirin 100 mg/day + clopidogrel 75 mg/day) for ≥3 months.
Exclusion: Cardioembolic stroke (e.g., with atrial fibrillation); Embolic stroke of undetermined source (ESUS); Perioperative stroke; Allergy to clopidogrel or aspirin; Bleeding tendency (e.g., thrombocytopenia or active gastrointestinal ulcer); History of recurrent miscarriage or current pregnancy; Malignancy or life expectancy <1 year; Requiring intravenous thrombolysis (rt-PA, urokinase, alteplase, or tenecteplase); Mechanical thrombectomy; Current use of anticoagulants (warfarin, rivaroxaban, dabigatran, etc.); Severe hepatic or renal dysfunction.